Bedard, P. L., Jhaveri, K. L., Accordino, M. K., Cervantes, P. A., Gambardella, V., Hamilton, E., Italiano, P. A., Kalinsky, P. K., Krop, P. I. E., Oliveira, M., Schmid, P. P., Saura, C., Turner, P. N., Varga, A., Cheeti, S., Dey, A., Hilz, S., Hutchinson, K. E., Jin, Y., … Juric, D. (2025). Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. European Journal of Cancer, 221, 115397. https://doi.org/10.1016/j.ejca.2025.115397

Jhaveri, K. L., Accordino, M. K., Bedard, P. L., Cervantes, A., Gambardella, V., Hamilton, E., Italiano, A., Kalinsky, K., Krop, I. E., Oliveira, M., Schmid, P., Saura, C., Turner, N. C., Varga, A., Cheeti, S., Hilz, S., Hutchinson, K. E., Jin, Y., Royer-Joo, S., … Juric, D. (2024). Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 42(33), 3947–3956. https://doi.org/10.1200/jco.24.00110

Thummar, K., & Rathinam, C. V. (2022). Class I PI3K regulatory subunits control differentiation of dendritic cell subsets and regulate Flt3L mediated signal transduction. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-16548-x